Modern pharmaceutical marketing operates at a delicate intersection between commerce and clinical care. A new review published in Pharmacia systematizes the multifaceted impact of marketing pressure on the rational use of medicines and dietary supplements, tracing the evolution of theoretical marketing frameworks through contemporary neuromarketing research and specific cognitive biases. The analysis covers regulatory filters in the European Union and Bulgaria, four categories of documented social consequences, and the clinical and psychological vulnerabilities of marketing directed at children and parents.
In this complex market reality, the strategic role of the pharmacist emerges as the ultimate clinical corrective. Pharmaceutical marketing occupies an autonomous niche within applied management disciplines. Mickey Smith, in his seminal works, defended the thesis that good marketing and good medicines are not only compatible but inseparable, as commercial decisions in this field have a direct impact on human health.
In modern theory, marketing is defined as a social and managerial process aimed at satisfying needs through the exchange of value. The historical evolution of marketing tools passes through four main stages: the Product Era from 1902 to 1929, focused entirely on production volume; the Commercial Era from 1930 to 1950, defined as the golden age of advertising driven by the rise of radio and television broadcasting and emotional slogans; the High-Quality Era from 1951 to 1980, a period of intensified competition in which market advantage was determined by the actual properties of the commodity; and the Digital Era from 1981 to the present, characterized by precise targeting, big data, and real-time tracking of consumer behavior. The operationalization of marketing in practice is traditionally achieved through the classic marketing mix of the Four Ps: Product, Price, Place, and Promotion.
Due to criticism that this framework primarily reflects the seller's perspective, modern social pharmacy applies the consumer-centric Four As framework: Acceptability, meaning the quality of the product matching and exceeding expectations; Affordability, meaning the socioeconomic feasibility of the price; Accessibility, meaning logistical ease of access and distribution; and Awareness, meaning high objective consumer awareness. In the pharmaceutical sector, Mickey Smith expanded this structure to the Five Ps, introducing the fundamental element of Positioning, a strategy for building a unique brand identity and value proposition based on parameters such as efficacy, safety, and tolerability. Translating market principles into pharmacy completely alters their dynamics due to several unique characteristics.
Unlike mass consumer markets, roles here are split among three independent entities: the physician selects the therapy as decision-maker, a third party such as the NHIF in Bulgaria finances it as payer, and the patient takes it as consumer. Patients, by definition, are reluctant to purchase medicines; they are acquired out of medical necessity, which amplifies public sensitivity to price levels. The life cycle of a pharmaceutical product undergoes specific phases from pre-introduction through launch, rapid growth, shake-out, maturity, decline, and withdrawal.
In this context, patent expiration leads to the phenomenon of the patent cliff, provoking a sharp decline in the price and market share of the original product due to the entry of lower-cost generics. For a long time, market research relied on verbal surveys, but modern neuroscience demonstrates that what people say they do and what they actually do are two different things. The brain collects approximately 11 million bits of information per second, of which the conscious mind processes only 40 bits.
The vast majority of consumer choices are made subconsciously. Neuromarketing examines the responses of the central nervous system and peripheral nervous system to marketing stimuli using tools such as electroencephalography, functional magnetic resonance imaging, eye-tracking, and galvanic skin responses. EEG captures mental effort with millisecond temporal precision, while eye-tracking fills the informational gap by showing exactly where the gaze is directed at that moment.
These techniques allow the preliminary evaluation of advertisements targeting the old, reptilian brain, the primitive part of the nervous system responsible for instincts and emotional reactions. When advertising utilizes comforting faces, children, or pleasant sounds, the biological route of suggestion overrides logical information. Advertising suggestion operates synchronously through several cognitive channels.
Evaluative conditioning, a mechanism from classical psychology transferred to pharmacy, works by repeatedly pairing a neutral stimulus such as the drug name with an emotionally charged scene like a smiling family, peaceful music, or pleasant colors, so the viewer's brain automatically transfers the positive affect from the scene onto the product. This attitude bypasses the rational assessment of benefits and risks, compromising patient autonomy. Authority bias reflects the innate inclination to trust competent figures and institutions.
Studies of medical materials sent to physicians show that authority is the second most commonly used marketing strategy at 29.4 percent, surpassed only by the principle of liking at 64.7 percent. Experimental data reveal a paradoxical finding: when physicians openly disclose their professional biases toward a certain therapy, patient trust does not decrease but rather increases. The fear of missing out represents a deep, constant anxiety that others are experiencing something valuable from which one is excluded.
In healthcare, this fear leads to heightened health anxiety and cyberchondria, a vicious cycle in which searching for medical symptoms online escalates panic and distorts the actual perception of risk. Emotional branding is based on Daniel Kahneman's two-system model of decision-making. Since purchasing choices are driven primarily by the fast and intuitive System 1 rather than the slow and rational System 2, companies invest in emotional brand communication.
This attachment transfer reduces price sensitivity and increases tolerance for higher prices. Interestingly, emotional communication often proves to be a strategy of the weaker market player that cannot compete on a purely rational or objective level. Due to low public trust in pharmaceutical corporations, brands redirect resources to social networks such as TikTok, Instagram, and Meta through the figure of the patient influencer.
A parasocial relationship, the illusion of personal friendship, is built between the consumer and the digital figure, which reduces the audience's skepticism because the content does not resemble a traditional advertisement. The link between the marketing message and the actual bodily response materializes in several large-scale modern phenomena. The rhetorical analysis of television commercials for Humira, a long-standing blockbuster, reveals the imposition of the curative imaginary concept: the advertisements do not sell a molecule but a visual standard of social normalcy and a fully functioning life.
However, cross-sectional studies reveal a severe ethnic disproportion in dermatological advertisements, with 92.6 percent White characters versus only 6.2 percent Black characters, which can systematically reinforce the misconception among minority groups that they are not at risk for certain diseases. Originally developed for type 2 diabetes, Ozempic gained widespread attention on social media platforms as a miracle drug for fast weight loss. Content analyses of advertisements on Meta indicate that 95.6 percent of targeted content is aimed at women, emphasizing the ideal of a thin body, while critical safety information is present in only 13 percent of cases.
This FOMO-driven marketing triggered global drug shortages and exposed consumers to off-label use with risks of pancreatitis and hypoglycemia. The omega-3 fatty acids case is the most vivid example of the gap between scientific evidence and marketing-constructed consumption. The extensive promotion of cardioprotection and cognitive function that began in the 1990s was challenged by three large-scale randomized controlled trials and a Cochrane meta-analysis, demonstrating no or clinically insignificant effects on mortality or cardiovascular events in healthy individuals.
Despite explicit European Society of Cardiology guidelines, the global market for omega-3 continues to grow substantially. Sales do not follow evidence; they follow marketing. Marketing signals alter the physiological response to therapy through established expectations.
Review publications define placebo and nocebo effects as pervasive in clinical practice. The marketing placebo effect means that a branded package, a high price, and an authoritative advertising message activate the ventromedial prefrontal cortex and the dopaminergic system, facilitating actual physiological relief. The mirror image, the marketing nocebo effect, leads to the onset or worsening of side effects due to negative expectations.
This phenomenon is critical for generic-heavy markets such as Bulgaria. Experimental data show that patients report significantly more adverse events when the same inert substance is labeled as a generic compared with being presented as an original brand. Media messages catalyze this process: studies of nationwide generic switches establish that broadcasting negative news stories increases reports of adverse drug reactions, with television having a 211 percent greater effect than print media.
The legal framework serves as a critical ethical filter, ensuring that commercial interests do not compromise safe treatment and patient compliance. Directive 2001/83/EC, the Community Code, defines the advertising of medicinal products and explicitly excludes objective information in leaflets and on packaging to preserve their impartial character. It requires objective presentation and the promotion of rational use, imposes a strict prohibition on public advertising of prescription-only medicines and drugs containing narcotic substances, and strictly prohibits suggestions of guaranteed therapeutic success.
The Law on Medicinal Products in Human Medicine details procedures for control in Bulgaria, introducing a broad definition of advertising activity covering direct consumer marketing, medical representative visits, sample distribution, and sponsorship of scientific congresses. Companies must maintain a scientific service, establishing a closed loop of safety in which medical representatives must report any adverse drug reaction reported by healthcare providers. Advertising content must correspond strictly to the approved Summary of Product Characteristics, eliminating off-label promotion, and all public advertising must undergo prior screening and approval by the Executive Director of the Bulgarian Drug Agency.
Dietary supplements fall under a distinct and significantly lighter regulatory regime, coordinated by the Food Law and Ordinance No. 1 of 11 October 2023, with the Bulgarian Food Safety Agency as the registration authority. Article 15 of Ordinance No. 1 categorically prohibits attributing therapeutic or preventive properties to dietary supplements, as well as suggesting that a balanced diet cannot provide the necessary nutrients, acting as a safeguard against patients underestimating prescribed conventional therapies or substituting non-curative products for them. Developing and marketing dosage forms tailored specifically for children represents one of the most complex and ethically sensitive areas in pharmacy.
Children are not simply small adults; they have entirely distinct pharmacokinetics and pharmacodynamics, requiring highly precise and flexible dosing adjusted to body weight or body surface area. Historically, the pediatric market has suffered from a severe deficit of age-appropriate products, frequently forcing healthcare providers to rely on off-label prescribing or the extemporaneous manipulation of adult solid dosage forms, which introduces a high risk of dosing errors and therapeutic failure. In pediatric pharmacotherapy, patient compliance depends critically on the organoleptic properties of the formulation.
The naturally bitter or metallic taste of many active pharmaceutical ingredients is the primary driver of medication refusal in children, causing profound psychological stress within families and compromising therapeutic adherence. Consequently, the pharmaceutical industry allocates significant research resources to advanced taste-masking technologies, including personalized flavoring systems that allow the customization of oral liquid vehicles according to the child's preference, and specialized drinking straws lined with taste-masking microgranules that dissolve during consumption of the liquid. Pharmaceutical marketing within the pediatric segment encounters a serious ethical paradox.
Digital advertising campaigns are increasingly targeted at mothers, who act as vulnerable decision-makers, by exploiting parental anxiety and protective guilt. Transforming a medicinal product into a highly attractive item by incorporating pleasant fruit flavors, gummy-bear shapes, or cartoon characters on the packaging poses a severe hazard. If a medication is engineered to be overly palatable and visually indistinguishable from confectionery, the risk of accidental self-administration by the child increases substantially, leading to severe toxic overdoses.
For this reason, regulatory bodies enforce strict mandates requiring child-resistant closures and standardized, unequivocal dosing syringes or spoons to eliminate the hazardous subjectivity associated with household spoons. Aggressive marketing and the normalization of preventive self-medication reflect four categories of systemic social consequences. The artificially constructed need for prevention drives the escalation of added polypharmacy, the simultaneous use of five or more products without clinical indications, and data indicate that OTC supplements contribute substantially to the incidence of drug-drug interactions.
Saturated by digital algorithms, patients arrive at the pharmacy or physician's office with a prepackaged internet diagnosis, expecting mere administrative confirmation, which erodes professional trust. Research establishes that only 23 percent of supplement users report their intake to their physicians, which leads to delays in seeking medical care and compromises adherence to the primary conventional therapy. Fear-based marketing maintains a vicious cycle of digital distress, as algorithms deliver new anxiety-inducing content immediately after a purchase, deepening clinical anxiety levels independently of baseline health literacy.
The trend of biohacking and longevity shapes consumer desires along socioeconomic lines, deepening health inequality. In households with limited financial resources, marketing pressure redirects funds away from essential healthcare toward commercially constructed needs, and analyses indicate that supplement polypharmacy is statistically more pronounced among groups with lower socioeconomic status. Pharmaceutical marketing has long ceased to be an isolated economic tool; it is a powerful therapeutic, psychobiological, and social force.
Traditional regulatory approaches, focused on the literal wording of the law, prove structurally insufficient against sophisticated digital persuasive techniques, influencer networks, and market-driven nocebo effects. This vulnerability is especially critical in pediatrics, where selecting a dosage form requires a careful balance among technological stability, palatability, and safety measures against accidental poisoning. In this context, the pharmacist occupies the strategic position of the final clinical filter in the healthcare system.
Their medical expertise and professional ethics can distinguish rational therapeutic use from marketing-driven consumption, identify critical interactions, and safeguard the patient's health and economic stability.
Subject of Research: Theoretical, psychological, and regulatory dimensions of modern pharmaceutical marketing: implications for patient behavior and healthcare systems
Article Title: Theoretical, psychological, and regulatory dimensions of modern pharmaceutical marketing: implications for patient behavior and healthcare systems
Article References: Politova, M., Karamancheva, L., Dimitrov, M., & Petkova, V. (2026). Theoretical, psychological, and regulatory dimensions of modern pharmaceutical marketing: implications for patient behavior and healthcare systems. Pharmacia, 73, Article e210485. https://doi.org/10.3897/pharmacia.73.e210485
Image Credits: AI Generated
DOI: 10.3897/pharmacia.73.e210485
Keywords: Theoretical, psychological, regulatory, dimensions, modern, pharmaceutical, marketing, implications, patient, behavior, healthcare, systems
Cite Scienmag News
Ophelia Keating. (October 20, 2026). Research report: Theoretical, psychological, and regulatory dimensions of modern pharmaceutical marketing: implications for patient behavior and healthcare systems. Scienmag. https://scienmag.com/research-report-theoretical-psychological-and-regulatory-dimensions-of-modern-pharmaceutical-marketing-implications-for-patient-behavior-and-healthcare-systems/
Ophelia Keating. "Research report: Theoretical, psychological, and regulatory dimensions of modern pharmaceutical marketing: implications for patient behavior and healthcare systems." Scienmag, 20 October 2026, https://scienmag.com/research-report-theoretical-psychological-and-regulatory-dimensions-of-modern-pharmaceutical-marketing-implications-for-patient-behavior-and-healthcare-systems/. Accessed 20 October 2026.
Ophelia Keating. "Research report: Theoretical, psychological, and regulatory dimensions of modern pharmaceutical marketing: implications for patient behavior and healthcare systems." Scienmag. October 20, 2026. https://scienmag.com/research-report-theoretical-psychological-and-regulatory-dimensions-of-modern-pharmaceutical-marketing-implications-for-patient-behavior-and-healthcare-systems/
